18642-23-4
18642-23-4 結(jié)構(gòu)式
基本信息
補(bǔ)骨酯定
補(bǔ)骨脂啶
補(bǔ)骨脂定對(duì)照品
補(bǔ)骨脂定, BR
補(bǔ)骨脂定(標(biāo)準(zhǔn)品)
PSORALIDIN 補(bǔ)骨脂定
PSORALIDIN 補(bǔ)骨脂定 標(biāo)準(zhǔn)品
3,9-二羥基-2-(3-甲基丁-2-烯-1-基)-6H-苯并呋喃并[3,2-C]苯并吡喃-6-酮
psoralidin
Psoralidin, BR
Psoralidin, >=99%
3,9-Dihydroxy-2-prenylcoumestan
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one
3,9-Dihydroxy-2-(3-methylbut-2-en-1-yl)-6H-benzofuro[3,2-c]chromen-6-one
3,9-Dihydroxy-2-(3-methyl-2-butenyl)-6H-benzofuro[3,2-c][1]benzopyran-6-one
6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)-
物理化學(xué)性質(zhì)
常見問題列表
|
COX-2
|
5-LOX
|
Three breast cancer cell (BCC)populations (ALDH
-
cells, ALDH
+
cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25?μM; 24?hours) with IC
50
s ranging from 18 to 21?μM; however, the MCF-12A cells were resistant to Psoralidin.
Psoralidin (30?μM; 24 hours) results in a significant induction of apoptosis for ALDH
-
cells, ALDH
+
cells, and commercial BCSCs.
Psoralidin treatment also downregulates NOTCH1 expression in both ALDH
-
and ALDH
+
cells.
Cell Viability Assay
| Cell Line: | ALDH - cells, ALDH + cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A) |
| Concentration: | 10, 15, 50, and 25 μM |
| Incubation Time: | 24?hours |
| Result: | IC 50 s of 18 to 21?μM for ALDH - cells, ALDH + cells, commercial BCSCs. |
Apoptosis Analysis
| Cell Line: | ALDH - cells, ALDH + cells, and commercial BCSCs |
| Concentration: | 20?and 30 μM |
| Incubation Time: | 24?hours |
| Result: | No significant induction of apoptosis was observed for any of the three cell types following treatment at 20?μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30?μMin ALDH - cells, ALDH + cells, and commercial BCSCs, respectively. |
Psoralidin (5 mg/kg) regulates expression of pro-inflammatory cytokines that play an important role in inflammatory diseasesin IR-irradiated lung of BALB/c mouse.
| Animal Model: | BALB/c mice |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy). |
| Result: | Anti-inflammatory effect in IR-irradiated mice. |